Benzinga | Jul 29, 2020 07:24AM EDT

Benchmark Maintains Buy on NeoGenomics, Raises Price Target to $40

Benchmark maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $35 to $40.